Standard Imaging, Inc.’s Post

Thank you for meeting with us at PMLS Precision Oncology & Diagnostics 2024 in Chicago! Our Chief Precision Medicine Officer, Susanne Munksted, delivered a talk on “Are We Closer to Fulfilling the Patient Promise of Precision Oncology?” This presentation expanded on insights from Diaceutics’ globally recognized Practice Gaps report, providing an update on how these practice gaps have evolved since 2022. Susanne also highlighted actionable steps the industry can take to address operational, economic, and policy challenges in precision medicine, drawing from the five key recommendations outlined by The Health and Economic Forum in the newly released Recommendations paper. For more information, and to download the recommendations paper, click the link below: https://lnkd.in/e7FnGF49 #PrecisionMedicine #BetterTestingBetterTreatement

Setting new landmarks to expand and improve the curative power of Radiotherapy! Can't wait to see how much potential can be unleashed from having a Clinical/Technical Training Center in the EIMEA Region #AccurayExpandRT #ContinuousImprovement #Hightech #healthcare

Come hear C. K. Wang and Wendy Turenne talk oncology RWD at #ISPORAnnual and stay for a demo of COTA's data on the Aetion Evidence Platform!

Celesta is delighted to lead the Series A round for OneCell Diagnostics Inc. 🧬 The capital will support OneCell's expansion into the U.S. market and continued development of its cutting-edge technology for precision oncology liquid biopsy diagnostics. Celesta's Founding Partner Michael E Marks, along with Senior Advisor and Biochemist Nobel Laureate Jim Rothman will join the company's board. Congratulations to CEO Mohan Uttarwar and the whole OneCell team! Read more about the funding in TechCrunch: https://lnkd.in/gkGF96RR

Susanne Munksted, Chief Precision Medicine Officer at Diaceutics, will be speaking at the PMLS Precision Oncology & Diagnostics 2024 tomorrow, Wednesday, 16th October, in Chicago. Susanne's presentation, “Are We Closer to Fulfilling the Patient Promise of Precision Oncology?”, will build on insights from the globally recognized 2022 Practice Gaps publication, providing an up-to-date review of the precision oncology landscape. Susanne will discuss actionable steps the industry can take to overcome the operational, economic, and policy challenges within precision medicine today, based on the five recommendations outlined by The Health and Economic Forum in the newly released Recommendations paper. If you’re attending the conference, make sure to pick up your copy of the paper!   #PrecisionMedicine #PrecisionOncology #PMLS2024 #GenomeWeb

Rising trends in payer reform, site-of-service evolution, and risk enablement are making a significant impact in oncology. Learn more about the industry’s progress, biggest challenges, and the value opportunity ahead: https://bit.ly/3A1n5xa

Photobiomodulation (PBM) for dry age-related macular degeneration, a leading cause of blindness #lowlevellaser #wellbeing #photobiomodulation #blindness #veterinaryphysiotherapy

Our blood travels through a circulatory network of arteries, veins and capillaries that is about 100,000 kilometers long. And it goes around thanks to our hearts beating about 100,000 times per day (some interesting symmetry). I won’t speculate how many times “blood actually goes around the body” per day, but what seems clear is that our hearts pump more than 1000 x of our total volume of blood per day. As it circulates through this extensive network, blood is enriched with information from every tissue and organ, information that can inform on our health and disease. And every company below👇🏾 is developing a technology that is pushing the boundaries of what can be learned from taking a small sample of blood, technologies that could radically impact how disease is detected and treated 🩸 Looking forward to the conversation, DeciBio #liquidbiopsy #healthcare

Join Regina Hargrove at #SROA2024 today at 3:45pm for "Hypofractionation: The Impacts of Clinical Advancements". This presentation will discuss the interplay between reimbursement dynamics, technological innovations, and clinical practice. This presentation aims to provide valuable insights for radiation oncology administrators grappling with the complexities of hypofractionation. Questions for our experts? Connect with them here or contact us at info@radiationbusiness.com.

After a few challenging years, 2024 has been exceptional for us. We achieved broad adoption of our first tumor profiling kit, Comprehensive Genomic Profiling OncoDEEP, and regained the growth that placed us among Deloitte's FAST50 winners in 2018 and 2020. Looking ahead, 2025 promises to be even more exciting with the launch of our second liquid biopsy kit OncoSELECT and innovations in minimal residual disease (MRD) detection. MRD is a hot topic for adoption in 2025, particularly in clinical and pharmaceutical research, as it enables earlier intervention and more precise treatment strategies. Stay tuned for more information coming very soon! #InnovationInOncology #LiquidBiopsy #MRD #CancerResearch #OncoDEEP #FAST50 #PrecisionMedicine